CL2008003494A1 - Compuestos derivados de 4-(2-amino-1-hidroxietil)fenol; composicion farmaceutica; combinacion; y uso de los compuestos como agonistas del receptor adrenergico beta2 para el tratamiento de una enfermedad pulmonar, asma, enfermedad pulmonar obstructiva cronica, glaucoma, trastornos neurologicos, trastornos cardiacos, inflamacion. - Google Patents

Compuestos derivados de 4-(2-amino-1-hidroxietil)fenol; composicion farmaceutica; combinacion; y uso de los compuestos como agonistas del receptor adrenergico beta2 para el tratamiento de una enfermedad pulmonar, asma, enfermedad pulmonar obstructiva cronica, glaucoma, trastornos neurologicos, trastornos cardiacos, inflamacion.

Info

Publication number
CL2008003494A1
CL2008003494A1 CL2008003494A CL2008003494A CL2008003494A1 CL 2008003494 A1 CL2008003494 A1 CL 2008003494A1 CL 2008003494 A CL2008003494 A CL 2008003494A CL 2008003494 A CL2008003494 A CL 2008003494A CL 2008003494 A1 CL2008003494 A1 CL 2008003494A1
Authority
CL
Chile
Prior art keywords
compounds
glaucoma
asthma
hydroxyethyl
phenol
Prior art date
Application number
CL2008003494A
Other languages
English (en)
Spanish (es)
Inventor
Puig Duran Carlos
Giulio Matassa Victor
Prat Quinones Maria
Sole Feu Laia
Liera Soldevila Oriol
Original Assignee
Laboratorios Almirall S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Almirall S A filed Critical Laboratorios Almirall S A
Publication of CL2008003494A1 publication Critical patent/CL2008003494A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2008003494A 2007-11-28 2008-11-24 Compuestos derivados de 4-(2-amino-1-hidroxietil)fenol; composicion farmaceutica; combinacion; y uso de los compuestos como agonistas del receptor adrenergico beta2 para el tratamiento de una enfermedad pulmonar, asma, enfermedad pulmonar obstructiva cronica, glaucoma, trastornos neurologicos, trastornos cardiacos, inflamacion. CL2008003494A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200703157A ES2320961B1 (es) 2007-11-28 2007-11-28 Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.

Publications (1)

Publication Number Publication Date
CL2008003494A1 true CL2008003494A1 (es) 2010-01-04

Family

ID=40451169

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003494A CL2008003494A1 (es) 2007-11-28 2008-11-24 Compuestos derivados de 4-(2-amino-1-hidroxietil)fenol; composicion farmaceutica; combinacion; y uso de los compuestos como agonistas del receptor adrenergico beta2 para el tratamiento de una enfermedad pulmonar, asma, enfermedad pulmonar obstructiva cronica, glaucoma, trastornos neurologicos, trastornos cardiacos, inflamacion.

Country Status (20)

Country Link
US (1) US8178679B2 (https=)
EP (1) EP2212276A1 (https=)
JP (1) JP2011505343A (https=)
KR (1) KR20100090248A (https=)
CN (1) CN101815700A (https=)
AR (1) AR069735A1 (https=)
AU (1) AU2008329193A1 (https=)
BR (1) BRPI0816597A2 (https=)
CA (1) CA2706333A1 (https=)
CL (1) CL2008003494A1 (https=)
CO (1) CO6210749A2 (https=)
ES (1) ES2320961B1 (https=)
MX (1) MX2010005623A (https=)
NZ (1) NZ583993A (https=)
PE (1) PE20091070A1 (https=)
RU (1) RU2010126063A (https=)
TW (1) TW200927111A (https=)
UY (1) UY31439A1 (https=)
WO (1) WO2009068177A1 (https=)
ZA (1) ZA201001818B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
MA38260B1 (fr) 2012-12-18 2018-04-30 Almirall Sa Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
TW201446767A (zh) 2013-02-15 2014-12-16 Almirall Sa 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
US10087191B2 (en) 2015-06-16 2018-10-02 Jiangsu Hengrui Medicine Co., Ltd. Piperidine derivative and preparation method and pharmaceutical use thereof
EP3484879B1 (en) * 2016-07-13 2020-12-30 Chiesi Farmaceutici S.p.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN106631717B (zh) * 2016-11-17 2019-11-22 上海再启生物技术有限公司 一种3-(2-氨基丙基)苯酚的制备方法
BR112020013152B1 (pt) * 2017-12-27 2023-05-09 Institut Pasteur De Montevideo Composto e composição farmacêutica

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT334335B (de) 1973-03-01 1976-01-10 Basf Ag Verfahren zur herstellung von 1-phenyl-2-aminoathanolen-(1)
US3053865A (en) 1958-03-19 1962-09-11 Merck & Co Inc Novel 16-alkyl and 16-alkylene steroids and processes
GB869511A (en) 1958-05-26 1961-05-31 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
US3007923A (en) 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
US3104246A (en) 1961-08-18 1963-09-17 Roussel Uclaf Process of preparation of beta-methasone
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
GB1247370A (en) 1968-12-31 1971-09-22 Allen & Hanburys Ltd Glyoxals and production thereof
US3678137A (en) 1970-10-15 1972-07-18 Smith Kline French Lab Adamantyl-substituted-alkyl 2-aminoethyl phosphates and phosphonates
BE786713A (fr) 1971-07-27 1973-01-25 Sandoz Sa Nouveaux amino-alcools, leur preparation et leur application comme medicaments
SE378109B (https=) 1972-05-19 1975-08-18 Bofors Ab
US4068076A (en) 1972-12-29 1978-01-10 Otsuka Pharmaceutical Co., Ltd. 5-(1-Hydroxy-2-(heterocyclic amino))ethyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
US3975391A (en) 1973-12-26 1976-08-17 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
DE2310140A1 (de) 1973-03-01 1974-09-12 Basf Ag Neue 1-phenyl-2-amino-aethanolderivate und ein verfahren zu ihrer herstellung
GB1468156A (en) 1973-07-19 1977-03-23 Ici Ltd Phenylethylamine derivatives
JPS5649907B2 (https=) 1974-02-01 1981-11-25
US4026897A (en) 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
US4022784A (en) 1974-01-31 1977-05-10 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-substituted-carbostyril and -3,4-dihydrocarbostyril derivatives
US4145542A (en) 1974-06-13 1979-03-20 Otsuka Pharmaceutical Co., Ltd. 5- 1-Hydroxy-2-(heterocyclic-amino)!alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
US3994901A (en) 1974-06-13 1976-11-30 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
JPS597706B2 (ja) 1975-06-13 1984-02-20 オオツカセイヤク カブシキガイシヤ カルボスチリルユウドウタイノセイゾウホウ
DE2965655D1 (en) 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
JPS6010032B2 (ja) 1983-10-31 1985-03-14 大塚製薬株式会社 カルボスチリル誘導体
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
NZ212367A (en) 1984-06-11 1989-04-26 Glaxo Group Ltd Ethanolamine derivatives and pharmaceutical compositions
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
JPS6485964A (en) 1987-03-12 1989-03-30 Glaxo Group Ltd Compound
AU609209B2 (en) 1987-11-13 1991-04-26 Glaxo Group Limited Phenethanolamine derivatives
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
JPH03178929A (ja) 1989-09-07 1991-08-02 Glaxo Group Ltd 炎症及びアレルギー治療用化合物
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
US5507281A (en) 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
DE69132850T2 (de) 1990-09-26 2002-05-29 Pharmachemie B.V., Haarlem Wirbelkammer-Pulverinhalator
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
DK0674533T3 (da) 1992-12-18 1999-09-27 Schering Corp Inhalator for medikamenter i pulverform
TR199701169T1 (xx) 1995-04-14 1998-03-21 Glaxo Wellcome Inc. Salmeterol i�in �l��lm�� doz inhaleri.
ATE209518T1 (de) 1995-06-21 2001-12-15 Asta Medica Ag Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
ES2171839T3 (es) 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
WO1998009632A1 (en) 1996-09-06 1998-03-12 Merck & Co., Inc. Methods and compositions for treating preterm labor
SE9704644D0 (sv) 1997-12-12 1997-12-12 Astra Ab New use
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
AUPQ407699A0 (en) 1999-11-16 1999-12-09 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
SI1775305T1 (sl) 2000-08-05 2015-01-30 Glaxo Group Limited S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-((2-furanilkarboksil)oksi)- 11beta-hidroksi-16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
WO2002092606A1 (en) 2001-05-15 2002-11-21 Takeda Chemical Industries, Ltd. Fused imidazolidine derivatives, process for preparation of the same and use thereof
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
JP2003188114A (ja) * 2001-12-18 2003-07-04 Oki Electric Ind Co Ltd 半導体素子の製造方法
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
JP2005523920A (ja) * 2002-04-25 2005-08-11 グラクソ　グループ　リミテッド フェネタノールアミン誘導体
WO2003099764A1 (en) * 2002-05-28 2003-12-04 Theravance, Inc. ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1622875B1 (en) * 2003-05-08 2009-12-02 Theravance, Inc. Crystalline forms of an arylaniline beta-2 adrenergic receptor agonist
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
EP1577291A1 (en) * 2004-03-17 2005-09-21 Pfizer Limited Phenylethanolamine derivatives as beta-2 agonists
BRPI0508927A (pt) * 2004-03-17 2007-08-14 Pfizer compostos úteis para o tratamento de doenças
EP1730103B1 (en) * 2004-03-23 2010-05-26 Pfizer Limited Formamide derivatives useful as adrenoceptor
CN1934071A (zh) * 2004-03-23 2007-03-21 辉瑞有限公司 可用作肾上腺素能受体的甲酰胺衍生物
CN1984876A (zh) 2004-06-03 2007-06-20 施万制药 二胺类β2肾上腺素能受体激动剂
WO2006014704A1 (en) * 2004-07-21 2006-02-09 Theravance, Inc. DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
GB0425057D0 (en) * 2004-11-12 2004-12-15 Pfizer Ltd L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide
US20060205949A1 (en) 2005-03-10 2006-09-14 Theravance, Inc. Crystalline forms of a biphenyl compound
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2296516B1 (es) 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2302447B1 (es) 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP2096105A1 (en) 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico

Also Published As

Publication number Publication date
CN101815700A (zh) 2010-08-25
AR069735A1 (es) 2010-02-17
RU2010126063A (ru) 2012-01-10
ES2320961A1 (es) 2009-05-29
TW200927111A (en) 2009-07-01
EP2212276A1 (en) 2010-08-04
CA2706333A1 (en) 2009-06-04
ZA201001818B (en) 2010-12-29
UY31439A1 (es) 2009-04-30
JP2011505343A (ja) 2011-02-24
CO6210749A2 (es) 2010-10-20
NZ583993A (en) 2011-11-25
US8178679B2 (en) 2012-05-15
AU2008329193A1 (en) 2009-06-04
KR20100090248A (ko) 2010-08-13
BRPI0816597A2 (pt) 2015-03-03
MX2010005623A (es) 2010-06-01
WO2009068177A1 (en) 2009-06-04
US20100324000A1 (en) 2010-12-23
ES2320961B1 (es) 2010-03-17
PE20091070A1 (es) 2009-07-23

Similar Documents

Publication Publication Date Title
CL2008003494A1 (es) Compuestos derivados de 4-(2-amino-1-hidroxietil)fenol; composicion farmaceutica; combinacion; y uso de los compuestos como agonistas del receptor adrenergico beta2 para el tratamiento de una enfermedad pulmonar, asma, enfermedad pulmonar obstructiva cronica, glaucoma, trastornos neurologicos, trastornos cardiacos, inflamacion.
UY29534A1 (es) Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor b(beta)2 adrenérgico.
CL2007002956A1 (es) Compuestos derivados de 4-(2-amino-1-hidroxietil)fenol, agonistas del receptor beta2 adrenergico; composicion farmaceutica, util para el tratamiento de una enfermedad pulmonar tal como asma y epoc, glaucoma, trastornos neurologicos y cardiacos, entre
CL2008001593A1 (es) Compuestos derivados de heterociclos, antagonistas para el ccr2; y uso de los compuestos para tratar afecciones o enfermedades del tracto respiratorio, como enfermedad pulmonar obstructiva cronica y asma.
GT200500284A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
ECSP19043120A (es) Pirrolopirimidinas como potenciadores de cftr
EA201200876A1 (ru) Новые антагонисты рецептора ccr2 и их применение
CO2019008986A2 (es) Derivados de tirosinamida como inhibidores de rho-quinasa
CL2009001247A1 (es) Compuestos derivados de 5-oxi/amino-indazol; moduladores del receptor de glucocorticoides; el proceso de preparacion de dichos compuestos; composiciones farmaceuticas que los contienen; combinacion farmaceutica; y su uso en el tratamiento de afecciones inflamatorias, trastornos respiratorios, asma y epoc.
CR9832A (es) Compuestos de pirimidina amida como inhibidores de pgds
CL2009000198A1 (es) Compuestos derivados del acido {2'-[(amino n,n-disustituido)-metil]-bifenil-3-il} acetico, mediadores de prostaglandina d2; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad respiratoria, alergica o inflamatoria, tal como el asma, epoc o rinitis alergica.
MX374537B (es) Tricíclicos sustituidos y método para usarlos.
UY31686A1 (es) Nueva dosificacion y formulacion
CL2012001298A1 (es) Compuestos derivados del acido carbomoil-metilamino acetico sustituido, inhibidores de nep; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de hipertension arterial, hipertension pulmonar, insuficiencia cardiaca, entre otras.
CL2011002787A1 (es) Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica.
GT200600193A (es) Imidazoquinolines como inhibidores de lipidos kinase
ECSP088741A (es) Derivados de benzotriazol como agonistas del adrenoreceptor beta2
CL2013003816A1 (es) Compuestos derivados de carboxamida y urea que comprende pirazol aromatico sustituido, ligantes del receptor de vanilloide; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis del dolor, migraña, enfermedad de parkinson, trastornos gastrointestinales, osteoporosis, entre otras enfermedades.
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
CL2009000120A1 (es) Compuestos derivados de carboxamidas n-aza-biciclicas; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso como antagonistas o agonistas del receptor tipo trpv1 para tratar el dolor, la inflamacion, trastornos metabolicos, urologicos, ginecologicos, gastrointestinales, respiratorios.
PE20221914A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
AR086745A1 (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CL2007002274A1 (es) Compuestos derivados del acido (3-amino-1,2,3,4-tetrahidro-9h-carbazol-9-il)-acetico; composicion farmaceutica; y uso para la prevencion y/o tratamiento de enfermedades alergicas e inmunes, tales como asma, epoc y rinitis entre otras.
CL2009000915A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd).